Reported Earlier, Abbisko And AstraZeneca Jointly Advance Novel IO-TKI Combination Therapy Evaluating Lumipodlin Plus Osimertinib In EGFR-Mutated PD-L1 Positive NSCLC Patients

Benzinga Newsdesk www.benzinga.com Positive 89.7%

Neg 0% Neu 0% Pos 89.7%

Comments

No comments yet. Be the first!